Indian Piramal Enterprises' US-based Pharma Solutions CDMO business has announced plans to expand its Aurora facility in Canada. The expansion will add a new state-of-the-art wing dedicated to manufacturing APIs.
A total investment of ~CAD$25 million will be infused towards this expansion.
Providing lab services and production plants, the Piramal Pharma Solutions' (PPS) Aurora facility will enhance its offerings to customers with this new addition that features ~10,500 sqft of new manufacturing space. The additional capacity will cater to increasing customer demand as well as support the facility's ability to provide APIs and HPAPIs down to an Occupational Exposure Limit (OEL) of 1 µg/m3.
The new expansion will also include filtration and drying capabilities that will enhance service offerings at Piramal Pharma Solutions' Aurora facility.
The expansion will add 10,500 sqft of new manufacturing space
Apart from the existing production-scale reactors, this expansion will include two new reactor suites as well as a dedicated filter dryer room and a portable filter dryer.
The expansion is expected to be completed and running by 30 April 2021. With successful inspections by the US FDA, the UK MHRA and the PMDA, Piramal Pharma Solutions' Aurora facility has a good track record of regulatory compliance and is committed to maintaining gold standards of environmental performance, health & safety.
Peter DeYoung, CEO of Piramal Pharma Solutions said: "This additional capacity will help us to strengthen our presence in Canada as well as service other geographies such as North America and Europe, whilst enabling us to support our customer's API requirements and market demand for integrated solutions.”
This upcoming facility has been designed to meet the high standards of global compliance and will employ highly qualified scientific, technical and professional staff, building on a business that has already seen staff numbers grow almost 2-fold to ~200 in recent years.
